Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)

598 Background: A phase II trial was conducted to show noninferiority of neoadjuvant CEX vs FEC. Methods: 182 patients (pts) with operable BC (T2–3, N0–1) were randomized (1:1) to four 3-weekly cyc...